Comments on 'Downregulation of hepatic ceruloplasmin ameliorates NAFLD via SCO1-AMPK-LKB1 complex'

J Mol Cell Biol. 2023 Aug 3;15(4):mjad026. doi: 10.1093/jmcb/mjad026.

Authors

Sijia Lu¹, Suzhen Chen¹, Ji Miao^{2

3}, Junli Liu¹

Affiliations

¹ Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.
² Division of Endocrinology, Boston Children's Hospital, Boston, MA 02215, USA.
³ Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

AMP-Activated Protein Kinases / metabolism
Ceruloplasmin
Down-Regulation
Humans
Liver / metabolism
Non-alcoholic Fatty Liver Disease*

Substances

AMP-Activated Protein Kinases
Ceruloplasmin

Grants and funding

R01 DK133331/DK/NIDDK NIH HHS/United States